Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Reporting of health-related quality of life endpoints in National Cancer Institute-supported cancer treatment trials.

St Germain D, Denicoff A, Torres A, Kelaghan J, McCaskill-Stevens W, Mishkin G, O'Mara A, Minasian LM.

Cancer. 2020 Apr 1. doi: 10.1002/cncr.32765. [Epub ahead of print]

PMID:
32237256
2.

Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era.

Roth ME, Unger JM, O'Mara AM, Lewis MA, Budd T, Johnson RH, Pollock BH, Blanke C, Freyer DR.

Cancer Med. 2020 Mar;9(6):2146-2152. doi: 10.1002/cam4.2891. Epub 2020 Feb 3.

3.

Sexual Dimorphisms in Adult Human Brown Adipose Tissue.

Fletcher LA, Kim K, Leitner BP, Cassimatis TM, O'Mara AE, Johnson JW, Halprin MS, McGehee SM, Brychta RJ, Cypess AM, Chen KY.

Obesity (Silver Spring). 2020 Feb;28(2):241-246. doi: 10.1002/oby.22698.

PMID:
31970907
4.

Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.

O'Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, Fink YA, Kapuria D, Cassimatis TM, Kelsey N, Cero C, Sater ZA, Piccinini F, Baskin AS, Leitner BP, Cai H, Millo CM, Dieckmann W, Walter M, Javitt NB, Rotman Y, Walter PJ, Ader M, Bergman RN, Herscovitch P, Chen KY, Cypess AM.

J Clin Invest. 2020 Mar 23. pii: 131126. doi: 10.1172/JCI131126. [Epub ahead of print]

5.

Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity.

Chen KY, Brychta RJ, Abdul Sater Z, Cassimatis TM, Cero C, Fletcher LA, Israni NS, Johnson JW, Lea HJ, Linderman JD, O'Mara AE, Zhu KY, Cypess AM.

J Biol Chem. 2020 Feb 14;295(7):1926-1942. doi: 10.1074/jbc.REV119.007363. Epub 2019 Dec 30. Review.

6.

Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.

Abdul Sater Z, Jha A, Hamimi A, Mandl A, Hartley IR, Gubbi S, Patel M, Gonzales M, Taïeb D, Civelek AC, Gharib AM, Auh S, O'Mara AE, Pacak K, Cypess AM.

J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: dgz314. doi: 10.1210/clinem/dgz314.

PMID:
31903484
7.

Building internal capacity in pragmatic trials: a workshop for program scientists at the US National Cancer Institute.

Norton WE, Zwarenstein M, Czajkowski S, Kato E, O'Mara A, Shelburne N, Chambers DA, Loudon K.

Trials. 2019 Dec 27;20(1):779. doi: 10.1186/s13063-019-3934-y.

8.

Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention.

Siembida EJ, Loomans-Kropp HA, Trivedi N, O'Mara A, Sung L, Tami-Maury I, Freyer DR, Roth M.

Cancer. 2020 Mar 1;126(5):949-957. doi: 10.1002/cncr.32675. Epub 2019 Dec 23. Review.

PMID:
31869454
9.

Evolution of Cancer Care Delivery Research in the NCI Community Oncology Research Program.

Geiger AM, O'Mara AM, McCaskill-Stevens WJ, Adjei B, Tuovenin P, Castro KM.

J Natl Cancer Inst. 2019 Dec 17. pii: djz234. doi: 10.1093/jnci/djz234. [Epub ahead of print]

PMID:
31845965
10.

Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors.

Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, Gavrilova N, Green PA, Jhappan C, Kohanski R, Krull K, Mandelblatt J, Ness KK, O'Mara A, Price N, Schrack J, Studenski S, Theou O, Tracy RP, Hurria A.

J Natl Cancer Inst. 2019 Dec 1;111(12):1245-1254. doi: 10.1093/jnci/djz136.

PMID:
31321426
11.

Whole Body and Regional Quantification of Active Human Brown Adipose Tissue Using 18F-FDG PET/CT.

Kim K, Huang S, Fletcher LA, O'Mara AE, Tal I, Brychta RJ, Cypess AM, Chen KY, Leitner BP.

J Vis Exp. 2019 Apr 1;(146). doi: 10.3791/58469.

PMID:
30985755
12.

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM.

J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.

13.

The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman DL, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Smith EL, Stevens WM, Janelsins MC.

J Natl Cancer Inst. 2019 Jun 1;111(6):531-537. doi: 10.1093/jnci/djz011.

PMID:
30715378
14.

Accurate and Unbiased Quantitation of Amyloid-β Fluorescence Images Using ImageSURF.

O'Mara AR, Collins JM, King AE, Vickers JC, Kirkcaldie MTK.

Curr Alzheimer Res. 2019;16(2):102-108. doi: 10.2174/1567205016666181212152622.

PMID:
30543169
15.

Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR.

J Clin Oncol. 2018 Sep 21:JCO2018786624. doi: 10.1200/JCO.2018.78.6624. [Epub ahead of print]

16.

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R.

Neurology. 2018 Aug 28;91(9):403-413. doi: 10.1212/WNL.0000000000006083. Epub 2018 Jul 27. Review.

17.

Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist.

Baskin AS, Linderman JD, Brychta RJ, McGehee S, Anflick-Chames E, Cero C, Johnson JW, O'Mara AE, Fletcher LA, Leitner BP, Duckworth CJ, Huang S, Cai H, Garraffo HM, Millo CM, Dieckmann W, Tolstikov V, Chen EY, Gao F, Narain NR, Kiebish MA, Walter PJ, Herscovitch P, Chen KY, Cypess AM.

Diabetes. 2018 Oct;67(10):2113-2125. doi: 10.2337/db18-0462. Epub 2018 Jul 6.

18.

Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.

Minasian LM, Frazier AL, Sung L, O'Mara A, Kelaghan J, Chang KW, Krailo M, Pollock BH, Reaman G, Freyer DR.

Cancer Med. 2018 May 30. doi: 10.1002/cam4.1563. [Epub ahead of print]

19.

Repeat propofol anesthesia does not exacerbate plaque deposition or synapse loss in APP/PS1 Alzheimer's disease mice.

Woodhouse A, Fernandez-Martos CM, Atkinson RAK, Hanson KA, Collins JM, O'Mara AR, Terblanche N, Skinner MW, Vickers JC, King AE.

BMC Anesthesiol. 2018 Apr 25;18(1):47. doi: 10.1186/s12871-018-0509-5.

20.

Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology.

Manfredsson FP, Luk KC, Benskey MJ, Gezer A, Garcia J, Kuhn NC, Sandoval IM, Patterson JR, O'Mara A, Yonkers R, Kordower JH.

Neurobiol Dis. 2018 Apr;112:106-118. doi: 10.1016/j.nbd.2018.01.008. Epub 2018 Jan 16.

21.

National Institutes of Health Research Plan on Rehabilitation: NIH Medical Rehabilitation Coordinating Committee.

NIH Medical Rehabilitation Coordinating Committee, O'Mara A, Rowland JH, Greenwell TN, Wiggs CL, Fleg J, Joseph L, McGowan J, Panagis JS, Washabaugh C, Peng GCY, Bray R, Cernich AN, Cruz TH, Marden S, Michel ME, Nitkin R, Quatrano L, Spong CY, Shekim L, Jones TLZ, Juliano-Bult D, Panchinson DM, Chen D, Jakeman L, Knebel A, Tully LA, Chan L, Damiano D, Tian B, McInnes P, Khalsa P, Reider E, Shurtleff D, Elwood W, Ballard R, Ershow AG, Begg L.

Phys Ther. 2017 Apr 1;97(4):104-407. doi: 10.1093/ptj/pzx026.

22.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.

23.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

24.

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.

JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.

25.

Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program.

Roth ME, O'Mara AM, Seibel NL, Dickens DS, Langevin AM, Pollock BH, Freyer DR.

J Oncol Pract. 2016 Apr;12(4):e388-95. doi: 10.1200/JOP.2015.009084. Epub 2016 Mar 29.

26.

Caring for caregivers and patients: Research and clinical priorities for informal cancer caregiving.

Kent EE, Rowland JH, Northouse L, Litzelman K, Chou WY, Shelburne N, Timura C, O'Mara A, Huss K.

Cancer. 2016 Jul 1;122(13):1987-95. doi: 10.1002/cncr.29939. Epub 2016 Mar 17. Review.

27.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group.

JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

28.

Survivorship care planning: unique opportunity to champion integrative oncology?

Rowland JH, O'Mara A.

J Natl Cancer Inst Monogr. 2014 Nov;2014(50):285. doi: 10.1093/jncimonographs/lgu037. No abstract available.

29.

What is cancer nursing research?

O'Mara A.

Cancer Nurs. 2015 Mar-Apr;38(2):81-2. doi: 10.1097/NCC.0000000000000228. No abstract available.

PMID:
25689041
30.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

31.

Hypoxia induces pluripotency in primordial germ cells by HIF1α stabilization and Oct4 deregulation.

López-Iglesias P, Alcaina Y, Tapia N, Sabour D, Arauzo-Bravo MJ, Sainz de la Maza D, Berra E, O'Mara AN, Nistal M, Ortega S, Donovan PJ, Schöler HR, De Miguel MP.

Antioxid Redox Signal. 2015 Jan 20;22(3):205-23. doi: 10.1089/ars.2014.5871. Epub 2014 Oct 30.

PMID:
25226357
32.

Clinical research education: perspectives of nurses, employers, and educators.

Galassi AL, Grady MA, O'Mara AM, Ness EA, Parreco LK, Belcher AE, Hastings CE.

J Nurs Educ. 2014 Aug;53(8):466-72. doi: 10.3928/01484834-20140724-04. Epub 2014 Jul 24.

PMID:
25050563
33.

Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, Minasian LM, Denicoff AM, O'Mara AM, Fisch MJ, Chauhan C, Aaronson NK, Coens C, Bruner DW.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju129. doi: 10.1093/jnci/dju129. Print 2014 Jul. Review.

34.

Nurse scientists in cancer cooperative groups.

Bruner DW, O'Mara A.

Semin Oncol Nurs. 2014 Feb;30(1):4-10. doi: 10.1016/j.soncn.2013.12.002. Epub 2013 Dec 18. Review.

PMID:
24559774
35.

Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors.

Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, Cleeland CS.

Cancer. 2014 Feb 1;120(3):425-32.

36.

Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors.

Fisch MJ, Zhao F, O'Mara AM, Wang XS, Cella D, Cleeland CS.

Cancer. 2014 Feb 1;120(3):442-50. doi: 10.1002/cncr.28437. Epub 2013 Oct 21.

37.

The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study.

Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ.

Cancer. 2013 Dec 15;119(24):4333-40. doi: 10.1002/cncr.28376. Epub 2013 Sep 24.

38.

Recommendations for high-priority research on cancer-related fatigue in children and adults.

Barsevick AM, Irwin MR, Hinds P, Miller A, Berger A, Jacobsen P, Ancoli-Israel S, Reeve BB, Mustian K, O'Mara A, Lai JS, Fisch M, Cella D; National Cancer Institute Clinical Trials Planning Meeting.

J Natl Cancer Inst. 2013 Oct 2;105(19):1432-40. doi: 10.1093/jnci/djt242. Epub 2013 Sep 18.

39.

Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E; NCI PRO-CTCAE Study Group.

Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.

40.

Regardless of where they give birth, women living in non-metropolitan areas are less likely to have an epidural than their metropolitan counterparts.

Powers JR, Loxton DJ, O'Mara AT, Chojenta CL, Ebert L.

Women Birth. 2013 Jun;26(2):e77-81. doi: 10.1016/j.wombi.2012.12.001. Epub 2012 Dec 29.

PMID:
23276587
41.

Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.

Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF; CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.

Cancer. 2013 Jan 15;119(2):411-20. doi: 10.1002/cncr.27744. Epub 2012 Aug 28.

42.

Improved outcomes in the malnourished patient: we're not there yet.

O'Mara A, St Germain D.

J Natl Cancer Inst. 2012 Mar 7;104(5):342-3. doi: 10.1093/jnci/djs031. Epub 2012 Feb 15. No abstract available.

PMID:
22345711
43.

Integrating pain metrics into oncology clinical trials.

Cleeland CS, O'Mara A, Zagari M, Baas C.

Clin Cancer Res. 2011 Nov 1;17(21):6646-50. doi: 10.1158/1078-0432.CCR-11-1109.

44.

Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM.

Transl Behav Med. 2011 Mar;1(1):110-22. doi: 10.1007/s13142-011-0025-3.

45.

Accrual to clinical trials: let's look at the physicians.

Minasian LM, O'Mara AM.

J Natl Cancer Inst. 2011 Mar 2;103(5):357-8. doi: 10.1093/jnci/djr018. Epub 2011 Feb 11. No abstract available.

PMID:
21317381
46.

Conducting chemoprevention clinical trials: challenges and solutions.

Richmond E, O'Mara A.

Semin Oncol. 2010 Aug;37(4):402-6. doi: 10.1053/j.seminoncol.2010.05.014. Review.

PMID:
20816509
47.

Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program.

Minasian LM, Carpenter WR, Weiner BJ, Anderson DE, McCaskill-Stevens W, Nelson S, Whitman C, Kelaghan J, O'Mara AM, Kaluzny AD.

Cancer. 2010 Oct 1;116(19):4440-9. doi: 10.1002/cncr.25248. Review.

48.

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials.

Barsevick AM, Cleeland CS, Manning DC, O'Mara AM, Reeve BB, Scott JA, Sloan JA; ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes).

J Pain Symptom Manage. 2010 Jun;39(6):1086-99. doi: 10.1016/j.jpainsymman.2010.02.006. Review.

49.

Health related quality of life in NCI-sponsored cancer treatment trials.

O'Mara AM, Denicoff AM.

Semin Oncol Nurs. 2010 Feb;26(1):68-78. doi: 10.1016/j.soncn.2009.11.009.

PMID:
20152580
50.

Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma.

Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, Noble S, McKillop IH, Schmidt CM.

J Surg Res. 2009 Jun 15;154(2):187-95. doi: 10.1016/j.jss.2008.11.836. Epub 2008 Dec 13.

Supplemental Content

Loading ...
Support Center